Table 2 Hazard ratios of BPH-related prostate surgery among men with BPH using finasteride or dutasteride
Finasteride | Dutasteride | Dutasteride vs finasteride | ||||||
|---|---|---|---|---|---|---|---|---|
Men with BPH-related surgery | PY at risk | Incidence per 1,000 PY (95 % CI) | Men with BPH-related surgery | PY at risk | Incidence per 1,000 PY (95 % CI) | Hazard ratio | ||
n (%)f | n (%)f | Crude (95 % CI)a | Adjusted (95 % CI) | |||||
Overall | 0.83 (0.62–1.10) | 0.75 (0.56–0.99)b | ||||||
Monotherapy | 86 (4) | 3,132 | 28 (22–34) | 108 (3) | 4,356 | 25 (20–30) | 0.85 (0.64–1.13) | 0.73 (0.54–0.98)c |
Combination therapy | 317 (9) | 5,646 | 56 (50–63) | 767 (9) | 12,685 | 61 (56–65) | 0.91 (0.80–1.04) | 0.85 (0.74–0.97)c |
Prescriber: GP | ||||||||
Monotherapy | 14 (1) | 1,201 | 12 (6–20) | 9 (1) | 915 | 10 (5–19) | 0.91 (0.39–2.13) | -g |
Combination therapy | 44 (4) | 1,710 | 26 (19–35) | 74 (4) | 2389 | 31 (24–39) | 1.07 (0.74–1.56) | 1.10 (0.76–1.60)d |
Prescriber: Urologist | ||||||||
Monotherapy | 26 (11) | 142 | 183 (120–268) | 45 (7) | 433 | 104 (76–139) | 0.56 (0.35–0.92) | 0.77 (0.46–1.30)d |
Combination therapy | 105 (24) | 223 | 472 (386–571) | 272 (16) | 1097 | 248 (219–279) | 0.53 (0.42–0.66) | 0.62 (0.50–0.78)e |